Disparities in stage at diagnosis for liver cancer in China
Background: The stage at diagnosis is a major factor in making treatment strategies and cancer control policies. However, the stage distribution for liver cancer in China was not well studied. In this multi-center hospital-based study, we aimed to identify the distribution and factors associated wit...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005422000965 |
| _version_ | 1811160156588736512 |
|---|---|
| author | Tianhao Shan Xianhui Ran Huizhang Li Guoshuang Feng Siwei Zhang Xuehong Zhang Lei Zhang Lingeng Lu Lan An Ruiying Fu Kexin Sun Shaoming Wang Ru Chen Li Li Wanqing Chen Wenqiang Wei Hongmei Zeng Jie He |
| author_facet | Tianhao Shan Xianhui Ran Huizhang Li Guoshuang Feng Siwei Zhang Xuehong Zhang Lei Zhang Lingeng Lu Lan An Ruiying Fu Kexin Sun Shaoming Wang Ru Chen Li Li Wanqing Chen Wenqiang Wei Hongmei Zeng Jie He |
| author_sort | Tianhao Shan |
| collection | DOAJ |
| description | Background: The stage at diagnosis is a major factor in making treatment strategies and cancer control policies. However, the stage distribution for liver cancer in China was not well studied. In this multi-center hospital-based study, we aimed to identify the distribution and factors associated with stage at diagnosis for liver cancer in China. Methods: We included patients diagnosed with primary liver cancer in 13 hospitals of 10 provinces covering various geographic and socioeconomic populations during 2016–2017 in China. The stage distribution overall, and by sex and age at diagnosis were analyzed. We used logistic regression to identify the factors associated with stage III-IV disease. We further compared these estimates with data from the USA. Results: We included 2,991 patients with known stage at diagnosis in China. The proportion of patients diagnosed with stage I, II, III, and IV was 17.5%, 25.6%, 29.3%, and 27.6%, respectively. The proportion of stage III-IV cases was higher in women [65.1% vs 54.9%, adjusted odds ratio (OR) = 1.5, 95% CI: 1.2, 1.8] and those ≥ 60 years (61.6% vs 52.8%, OR = 1.4, 95% CI: 1.2, 1.6). We found an increased risk of stage III-IV among drinkers and those without a family history of cancer. Compared to the USA, our study population had a substantially higher proportion of stage III-IV cases (56.9% vs 45.6%). Conclusion: The disparities in liver cancer stage at diagnosis among different populations within China, and between China and the USA, imply the necessity for improving cancer awareness and early detection for liver cancer in China. |
| first_indexed | 2024-04-10T05:52:50Z |
| format | Article |
| id | doaj.art-5a63478041914101b90f8cefa09e67eb |
| institution | Directory Open Access Journal |
| issn | 2667-0054 |
| language | English |
| last_indexed | 2024-04-10T05:52:50Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj.art-5a63478041914101b90f8cefa09e67eb2023-03-04T04:24:06ZengElsevierJournal of the National Cancer Center2667-00542023-03-0131713Disparities in stage at diagnosis for liver cancer in ChinaTianhao Shan0Xianhui Ran1Huizhang Li2Guoshuang Feng3Siwei Zhang4Xuehong Zhang5Lei Zhang6Lingeng Lu7Lan An8Ruiying Fu9Kexin Sun10Shaoming Wang11Ru Chen12Li Li13Wanqing Chen14Wenqiang Wei15Hongmei Zeng16Jie He17National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCancer Hospital of University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Department of Cancer Prevention, Institute of Cancer Research and Basic Medical Sciences, Chinese Academy of Sciences, Hangzhou, ChinaBig Data Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; Department of Nutrition, T.H. Chan School of Public Health, Harvard University, Boston, USAChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China; Artificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia; Central Clinical School, Faculty of Medicine, Monash University, Melbourne, Australia; Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, ChinaDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale Cancer Center, New Haven, USANational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding authors.Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding authors.Background: The stage at diagnosis is a major factor in making treatment strategies and cancer control policies. However, the stage distribution for liver cancer in China was not well studied. In this multi-center hospital-based study, we aimed to identify the distribution and factors associated with stage at diagnosis for liver cancer in China. Methods: We included patients diagnosed with primary liver cancer in 13 hospitals of 10 provinces covering various geographic and socioeconomic populations during 2016–2017 in China. The stage distribution overall, and by sex and age at diagnosis were analyzed. We used logistic regression to identify the factors associated with stage III-IV disease. We further compared these estimates with data from the USA. Results: We included 2,991 patients with known stage at diagnosis in China. The proportion of patients diagnosed with stage I, II, III, and IV was 17.5%, 25.6%, 29.3%, and 27.6%, respectively. The proportion of stage III-IV cases was higher in women [65.1% vs 54.9%, adjusted odds ratio (OR) = 1.5, 95% CI: 1.2, 1.8] and those ≥ 60 years (61.6% vs 52.8%, OR = 1.4, 95% CI: 1.2, 1.6). We found an increased risk of stage III-IV among drinkers and those without a family history of cancer. Compared to the USA, our study population had a substantially higher proportion of stage III-IV cases (56.9% vs 45.6%). Conclusion: The disparities in liver cancer stage at diagnosis among different populations within China, and between China and the USA, imply the necessity for improving cancer awareness and early detection for liver cancer in China.http://www.sciencedirect.com/science/article/pii/S2667005422000965Liver cancerStage at diagnosisDisparityChinaUSA |
| spellingShingle | Tianhao Shan Xianhui Ran Huizhang Li Guoshuang Feng Siwei Zhang Xuehong Zhang Lei Zhang Lingeng Lu Lan An Ruiying Fu Kexin Sun Shaoming Wang Ru Chen Li Li Wanqing Chen Wenqiang Wei Hongmei Zeng Jie He Disparities in stage at diagnosis for liver cancer in China Journal of the National Cancer Center Liver cancer Stage at diagnosis Disparity China USA |
| title | Disparities in stage at diagnosis for liver cancer in China |
| title_full | Disparities in stage at diagnosis for liver cancer in China |
| title_fullStr | Disparities in stage at diagnosis for liver cancer in China |
| title_full_unstemmed | Disparities in stage at diagnosis for liver cancer in China |
| title_short | Disparities in stage at diagnosis for liver cancer in China |
| title_sort | disparities in stage at diagnosis for liver cancer in china |
| topic | Liver cancer Stage at diagnosis Disparity China USA |
| url | http://www.sciencedirect.com/science/article/pii/S2667005422000965 |
| work_keys_str_mv | AT tianhaoshan disparitiesinstageatdiagnosisforlivercancerinchina AT xianhuiran disparitiesinstageatdiagnosisforlivercancerinchina AT huizhangli disparitiesinstageatdiagnosisforlivercancerinchina AT guoshuangfeng disparitiesinstageatdiagnosisforlivercancerinchina AT siweizhang disparitiesinstageatdiagnosisforlivercancerinchina AT xuehongzhang disparitiesinstageatdiagnosisforlivercancerinchina AT leizhang disparitiesinstageatdiagnosisforlivercancerinchina AT lingenglu disparitiesinstageatdiagnosisforlivercancerinchina AT lanan disparitiesinstageatdiagnosisforlivercancerinchina AT ruiyingfu disparitiesinstageatdiagnosisforlivercancerinchina AT kexinsun disparitiesinstageatdiagnosisforlivercancerinchina AT shaomingwang disparitiesinstageatdiagnosisforlivercancerinchina AT ruchen disparitiesinstageatdiagnosisforlivercancerinchina AT lili disparitiesinstageatdiagnosisforlivercancerinchina AT wanqingchen disparitiesinstageatdiagnosisforlivercancerinchina AT wenqiangwei disparitiesinstageatdiagnosisforlivercancerinchina AT hongmeizeng disparitiesinstageatdiagnosisforlivercancerinchina AT jiehe disparitiesinstageatdiagnosisforlivercancerinchina |